Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?

Table 2

The evolution of urgency in the course of the study.

Variable	Baseline; n (%) [B]	Week 1; n (%) [W1]	Week 6; n (%) [W6]	Statistical analyses inside each group
Control group; (n=110); C	29 (26.4)	66 (60.0)	23 (20.9)	B vs. W1, p <0.001; B vs. W6, NS; W1 vs. W6, p <0.001
Treatment group 1; (10 mg of solifenacin); (n=114); S	35 (30.7)	43 (37.7)	11 (9.7)	B vs. W1, NS; B vs. W6, p < 0.001; W1 vs. W6, p < 0.001
Treatment group 2; (50 mg of mirabegron); (n=104); M	26 (25)	43 (41.3)	23 (22.1)	B vs. W1, p<0.05; B vs. W6, NS; W1 vs. W6, p<0.005

Baseline: C vs. S (NS); C vs. M (NS); S vs. M (NS).
Week 1: C vs. S (p <0.001); C vs. M (p <0.001); S vs. M (NS).
Week 6: C vs. S (p<0.05); C vs. M (NS); S vs. M (p<0.05).